Creative Medical Technology Holdings, Inc.
CELZ$1.15
+$0.48 (71.95%)+71.95%
After HoursCreative Medical Technology raises ~$4.5M via warrant exercises, issues new 5-year warrants for up to 5.58M shares at $1.60
Loading chart...
IndexN/A
Market Cap0.00B
Enterprise Value-0.00B
Income$-0.00B
Sales$0.00B
EmployeesN/A
P/E-0.54
P/S778.38
P/B0.62
P/C-0.80
EV/EBITDA0.42
EV/SalesN/A
EPS (ttm)-2.14
EarningsN/A
Gross Margin63.43%
Oper. Margin-102380.23%
Profit Margin-99916.80%
Volume267.24M
Shs Outstand0.00B
Change71.95%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.00K | $9.00K | $88.60K | $87.75K | $164.50K | $165.50K | $124.40K | $4.80K |
| Cost of Revenue | $4.40K | $3.60K | $28.49K | $47.95K | $50.60K | $45.50K | $70.38K | $8.00K |
| Gross Profit | $6.60K | $5.40K | $60.11K | $39.80K | $113.90K | $120.00K | $54.02K | $-3.20K |
| Gross Margin | 60.00% | 60.00% | 67.84% | 45.36% | 69.24% | 72.51% | 43.43% | -66.67% |
| Operating Expenses | $5.75M | $5.63M | $10.30M | $3.17M | $1.23M | $1.25M | $1.17M | $1.17M |
| Operating Income | $-5.74M | $-5.62M | $-10.24M | $-3.13M | $-1.11M | $-1.13M | $-1.11M | $-1.18M |
| Operating Margin | -52216.92% | -62445.91% | -11562.50% | -3562.17% | -677.71% | -682.88% | -895.68% | -24537.63% |
| Net Income | $-5.49M | $-5.29M | $-10.14M | $19.21M | $-36.33M | $-8.48M | $-13.66M | $-2.66M |
| Net Margin | -49940.74% | -58739.71% | -11449.26% | 21892.75% | -22082.21% | -5126.09% | -10977.21% | -55398.08% |
| EPS (Basic) | $-3.71 | $-3.76 | $-9.28 | $73.75 | $-626.88 | $-5017.67 | $-11351.33 | $-17379.79 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
Creative Medical Technology Stock Surges After Key Patent Winbenzinga.com Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platformsglobenewswire.com Creative Medical Technology Holdings Issues Mid-Year Updateglobenewswire.com Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.5 Million Gross Proceedsglobenewswire.com Creative Medical Technology Holdings Expands ADAPT Trial Under New FDA Clearance and Rapidly Advances Toward Phase 3 Planning for Olastrocel in Chronic Lower Back Painglobenewswire.com Creative Medical Technology opens nationwide burn-pit data registryproactiveinvestors.com Creative Medical Technology opens nationwide burn-pit data registryproactiveinvestors.com Creative Medical Technology Holdings, Inc. Advances Project PHOENIX into Nationwide AI Driven Virtual Data Collection Phase for U.S. Veterans Exposed to Burn Pits and Toxic Hazardsglobenewswire.com
Show 12 more stories
Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome™ Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapiesglobenewswire.com Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Painglobenewswire.com Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiativeglobenewswire.com Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Pointglobenewswire.com Creative Medical Technology Holdings Announces World Health Organization Approval of “olastrocel” as INN for Lead Allogeneic Cell Therapy CELZ-201globenewswire.com Bears are Losing Control Over Creative Medical Technology Holdings, Inc. (CELZ), Here's Why It's a 'Buy' Nowzacks.com Creative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn Pitsglobenewswire.com Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.2 Million Gross Proceedsglobenewswire.com Creative Medical Technology Holdings Issues Letter to Shareholdersglobenewswire.com Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughsglobenewswire.com New Strong Sell Stocks for July 31stzacks.com Creative Medical Technology Holdings Receives Notice of Allowance for the Prevention and/or Treatment of Type 1 Diabetes Using Modulated Immune Cellsglobenewswire.com
Insider Trading
No insider trades found for CELZ.
Company
About the company
Creative Medical Technology Holdings, Inc., a biotechnology firm based in Phoenix, Arizona, specializes in advancing adult stem cell treatments. The company's core focus spans several medical fields, including immunology, urology, orthopedics, and neurology. Among its therapeutic offerings are CaverStem, designed to address erectile dysfunction; FemCelz, which aims to restore genital sensitivity and alleviate dryness; StemSpine, developed to treat chronic lower back pain; ImmCelz, intended for stroke patients; and OvaStem, a solution for female infertility.
Discover more
You may be interested in